



- (51) International Patent Classification:
A61K 39/09 (2006.01)
- (21) International Application Number:
PCT/US2024/029593
- (22) International Filing Date:
16 May 2024 (16.05.2024)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
63/553,366 14 February 2024 (14.02.2024) US
- (71) Applicant: **MERCK SHARP & DOHME LLC** [US/US];
126 East Lincoln Avenue, Rahway, New Jersey 07065 (US).
- (72) Inventors: **BUCHWALD, Ulrike K.**; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US). **JOSHI, Rennie**; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US). **JOYCE, Joseph G.**; 14 Glen Road, Lansdale, Pennsylvania 19446 (US). **MALINVERNI, Juliana C.**; 126

East Lincoln Avenue, Rahway, New Jersey 07065 (US). **MONSLOW, Morgan A.**; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US). **OLMSTEAD, Adam G. C.**; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US). **SADDIER, Patricia**; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US). **SMITH, William J.**; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US). **VELENT-GAS, Priscilla T.**; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US).

(74) Agent: **LEFF, Matthew A.**; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: 26-VALENT PNEUMOCOCCAL CONJUGATE VACCINES AND METHODS OF USE THEREOF




FIG. 1

(57) Abstract: The invention is related to 26-valent immunogenic compositions comprising 26 different *S. pneumoniae* polysaccharide carrier protein conjugates, wherein each of the conjugates comprises a polysaccharide from an *S. pneumoniae* serotype conjugated to a carrier protein, wherein the serotypes of *S. pneumoniae* are as defined herein. The 26-valent immunogenic compositions are useful for providing protection against *S. pneumoniae* infection and/or pneumococcal diseases caused by *S. pneumoniae* including pneumococcal pneumoniae, invasive pneumococcal disease and acute otitis media.

[Continued on next page]

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*